Inhibikase Therapeutics (IKT) EBITDA Yield: History & Chart

Inhibikase Therapeutics, Inc.(IKT)

Biotechnology · Wilmington, DE

$2.02+0.02 (+0.92%)

Delayed quote: Oct 6, 2026, 12:15 PM EDT

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Wilmington, DE

35 employees

www.inhibikase.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mark T. Iwicki

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Inhibikase Therapeutics, Inc. (IKT)	$266.51M	N/A	N/A	N/A	N/A
Eupraxia Pharmaceuticals Inc. (EPRX)vs ›	$266.78M	N/A	N/A	N/A	N/A
OraSure Technologies, Inc. (OSUR)vs ›	$267.70M	N/A	55.26%	33.09%	19.40%
EyePoint Pharmaceuticals, Inc. (EYPT)vs ›	$268.35M	N/A	10.04%	10.04%	9.67%
Lexeo Therapeutics, Inc. Common Stock (LXEO)vs ›	$263.44M	N/A	N/A	N/A	N/A
Palisade Bio, Inc. (PALI)vs ›	$261.58M	N/A	0.00%	0.00%	0.00%
Rocket Pharmaceuticals, Inc. (RCKT)vs ›	$275.17M	N/A	N/A	N/A	N/A
Scribe Therapeutics Inc. (SCTX)vs ›	$274.77M	N/A	N/A	N/A	N/A
Anika Therapeutics, Inc. (ANIK)vs ›	$257.56M	0.21%	12.97%	7.82%	5.93%
AC Immune S.A. (ACIU)vs ›	$256.39M	N/A	11.24%	13.49%	12.26%

NAME

MARKET CAP

EBITDA YIELD

TTM

Inhibikase Therapeutics, Inc. (IKT)

$266.51M

N/A

Eupraxia Pharmaceuticals Inc. (EPRX)vs ›

$266.78M

N/A

OraSure Technologies, Inc. (OSUR)vs ›

$267.70M

N/A

55.26%

33.09%

19.40%

EyePoint Pharmaceuticals, Inc. (EYPT)vs ›

$268.35M

N/A

10.04%

9.67%

Lexeo Therapeutics, Inc. Common Stock (LXEO)vs ›

$263.44M

N/A

Palisade Bio, Inc. (PALI)vs ›

$261.58M

N/A

0.00%

Rocket Pharmaceuticals, Inc. (RCKT)vs ›

$275.17M

N/A

Scribe Therapeutics Inc. (SCTX)vs ›

$274.77M

N/A

Anika Therapeutics, Inc. (ANIK)vs ›

$257.56M

0.21%

12.97%

7.82%

5.93%

AC Immune S.A. (ACIU)vs ›

$256.39M

N/A

11.24%

13.49%

12.26%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

IKT EBITDA Yield Metrics

IKT Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics